# Rishabh Instruments — Operating Leverage Inflection | Target ₹850–950
**NSE: RISHABH | CMP ₹512 | MCap ₹1,979 Cr | Timeframe: 12–18 months**
---
## Business Model
Rishabh Instruments is a Nashik-based precision instrumentation company operating across three segments:
- **EEI (Electrical & Electronics Instrumentation)** — Panel meters, current transformers (CTs), power quality analyzers. Claims to be the largest CT manufacturer in the world. High-margin, IP-driven business with 60–70% gross margins on premium SKUs.
- **Lumel SA (Poland subsidiary)** — Industrial automation and measurement equipment sold across Europe. Expanded into Alucast, a die-casting division now turned profitable after a multi-year restructuring.
- **Solar Inverters** — Early-stage, growing segment. Still margin-dilutive but scaling rapidly (guidance to double revenue FY27).
Revenue is geographically diversified: India, US (+53% YoY), UK (+25%), China (+23%), Europe. This is not a pure domestic play — it has genuine global product acceptance.
---
## Moat
Three overlapping moats that are hard to replicate:
1. **Technical certification barriers** — Products require SIL 1/SIL 2 qualification in Europe, UL certification in the US, and BIS approvals in India. These take years and millions to obtain. New entrants cannot shortcut this.
2. **Scale in CTs** — Being the world's largest CT manufacturer means cost-per-unit advantages that pricing cannot be matched by smaller players. Utilities and panel builders do not switch CT suppliers easily.
3. **EU-funded infrastructure** — Commissioned Europe's most advanced SMT assembly line, 40% funded by the European Union. This gives Lumel a cost and quality edge in European markets that no private competitor can easily match.
4. **ESG mandate tailwind** — ISO 50000 energy efficiency mandates across Europe are a structural, policy-driven demand driver for their energy measurement products. This is not cyclical.
---
## Financial Snapshot
| Metric | Value |
|---|---|
| CMP | ₹512 |
| Market Cap | ₹1,979 Cr |
| P/E | 24x (vs 36x three years ago — PE compressed despite PAT tripling) |
| Debt / Equity | 0.10 — near debt-free |
| Interest Coverage | 20x |
| Promoter Holding | 69.55% — very high, aligned |
**Operating margin trajectory (quarterly):**
Q1 FY26 → Q2 → Q3 → Q4: **14.9% → 17.0% → 17.1% → 16.3%**
Annual OPM: 6.7% (FY25) → **16.3% (FY26)** — expanded 960 basis points in one year.
**ROCE trajectory:**
FY25: 5.05% → FY26: **13.6%** — near tripling in 12 months.
**PAT growth TTM: +291%**
Revenue growth TTM: +7.6% — profit growing 38x faster than revenue. This is pure operating leverage — fixed costs getting absorbed at scale.
**PAT quarterly (₹Cr):** 19.6 → 22.1 → 20.5 → 20.0
Stable, not lumpy. No single-quarter spike distorting the picture.
---
## Management Commentary (Q4 FY26 Concall — May 2026)
Management tone score: **9/10** — one of the most credible concalls reviewed.
Key statements that build conviction:
- **Guided 20–22% EBITDA margins for FY27** — actively talked analysts DOWN from Q4's 23.9% to avoid overpromising. This is unusual and highly credible.
- **20–25% top-line growth guidance for EEI segment** — with near-full capacity today, this is backed by the Nashik capacity doubling commissioning June/July 2026.
- **US business target: ₹100 Cr in 3–4 years** — from near-zero today. One UL certification unlock = significant rerating.
- **Alucast demerger hinted** — "a possibility." If executed, this unlocks hidden value currently being discounted by the market due to the division's historical losses.
- **Dividend declared** — ₹2/share, signalling confidence in cash flows.
- **On solar:** "The more you sell, the more losses we were making — that is gone now." Breakeven crossed. Volume scale from here is margin-accretive.
One concern management flagged honestly: Lumel Alucast top-line will remain flat in FY27 as it rebuilds its contract book after shedding loss-making clients. This is a known, temporary drag — not a structural problem.
---
## Why Now — The Setup
- **PE compression paradox:** PE has gone from 36x (3 years ago) to 24x today — even as PAT has tripled. The stock is cheaper on earnings than it was when the business was weaker. This gap closes violently when institutions notice.
- **Capacity coming online:** Nashik doubling commissions June/July 2026. Revenue step-up is weeks away, not years.
- **CRS vs Nifty500 (50D): +44** — stock is significantly outperforming the broader market on a relative strength basis. Momentum is with the stock.
- **EMA alignment:** CMP ₹512 > EMA50 ₹482 > EMA200 ₹418. Bullish stack. No resistance overhead.
- **52-week high proximity:** Only 6 days since the last 52-week high. Stock is not tired — it is breaking out.
- **MCap ₹1,979 Cr** — small enough that one institutional discovery = 30–50% move.
---
## Buy Zone / Targets / Stop Loss
**Preferred entry zone: ₹490–520**
Current CMP ₹512 is inside the buy zone. Any dip toward EMA50 (₹482) is a gift entry.
**Do not chase above ₹545** — wait for a retest if missed.
| Target | Price | Basis | Timeline |
|---|---|---|---|
| Target 1 | ₹700 | PE re-rating to 32x on FY27E EPS of ~₹22 | 6–9 months |
| Target 2 | ₹850 | PE 36x on FY27E EPS — back to historical multiple | 12 months |
| Target 3 | ₹950 | Alucast demerger or US UL certification catalyst | 12–18 months |
**Stop Loss: ₹420** (just below EMA200 of ₹418)
A close below ₹420 invalidates the operating leverage thesis — exit cleanly.
**Risk/Reward:**
- Risk from CMP: ~18% downside to stop
- Reward to T2: ~66% upside
- Risk/Reward ratio: **~3.7:1**
---
## Key Risks to Monitor
1. **Solar inverter scaling slower than guided** — margin dilutive until breakeven volumes hit
2. **Alucast contract rebuild stalls** — top-line flat FY27 is known; any further deterioration is a red flag
3. **US UL certification delays** — the US ₹100 Cr target depends on approvals that involve "high costs, redesigns, and long lab queues" per management
4. **Global macro slowdown** — European demand subdued, any further weakness hurts Lumel revenue
---
## Summary
Rishabh Instruments is a rare combination: **globally competitive product, world-scale manufacturing in one niche (CTs), near-debt-free balance sheet, promoter holding 70%, OPM expanding 960bps in 12 months, PAT up 291% TTM, and a PE that has actually compressed.**
The market has not yet connected the dots between the earnings reality and the valuation. That gap is the opportunity.
The Nashik capacity doubling in June/July 2026 is the near-term trigger. The Alucast demerger and US expansion are the medium-term optionality.
**Buy ₹490–520 | Stop ₹420 | Target ₹850–950 | Timeframe 12–18 months**
*This is a research idea, not investment advice. Do your own due diligence.*
**NSE: RISHABH | CMP ₹512 | MCap ₹1,979 Cr | Timeframe: 12–18 months**
---
## Business Model
Rishabh Instruments is a Nashik-based precision instrumentation company operating across three segments:
- **EEI (Electrical & Electronics Instrumentation)** — Panel meters, current transformers (CTs), power quality analyzers. Claims to be the largest CT manufacturer in the world. High-margin, IP-driven business with 60–70% gross margins on premium SKUs.
- **Lumel SA (Poland subsidiary)** — Industrial automation and measurement equipment sold across Europe. Expanded into Alucast, a die-casting division now turned profitable after a multi-year restructuring.
- **Solar Inverters** — Early-stage, growing segment. Still margin-dilutive but scaling rapidly (guidance to double revenue FY27).
Revenue is geographically diversified: India, US (+53% YoY), UK (+25%), China (+23%), Europe. This is not a pure domestic play — it has genuine global product acceptance.
---
## Moat
Three overlapping moats that are hard to replicate:
1. **Technical certification barriers** — Products require SIL 1/SIL 2 qualification in Europe, UL certification in the US, and BIS approvals in India. These take years and millions to obtain. New entrants cannot shortcut this.
2. **Scale in CTs** — Being the world's largest CT manufacturer means cost-per-unit advantages that pricing cannot be matched by smaller players. Utilities and panel builders do not switch CT suppliers easily.
3. **EU-funded infrastructure** — Commissioned Europe's most advanced SMT assembly line, 40% funded by the European Union. This gives Lumel a cost and quality edge in European markets that no private competitor can easily match.
4. **ESG mandate tailwind** — ISO 50000 energy efficiency mandates across Europe are a structural, policy-driven demand driver for their energy measurement products. This is not cyclical.
---
## Financial Snapshot
| Metric | Value |
|---|---|
| CMP | ₹512 |
| Market Cap | ₹1,979 Cr |
| P/E | 24x (vs 36x three years ago — PE compressed despite PAT tripling) |
| Debt / Equity | 0.10 — near debt-free |
| Interest Coverage | 20x |
| Promoter Holding | 69.55% — very high, aligned |
**Operating margin trajectory (quarterly):**
Q1 FY26 → Q2 → Q3 → Q4: **14.9% → 17.0% → 17.1% → 16.3%**
Annual OPM: 6.7% (FY25) → **16.3% (FY26)** — expanded 960 basis points in one year.
**ROCE trajectory:**
FY25: 5.05% → FY26: **13.6%** — near tripling in 12 months.
**PAT growth TTM: +291%**
Revenue growth TTM: +7.6% — profit growing 38x faster than revenue. This is pure operating leverage — fixed costs getting absorbed at scale.
**PAT quarterly (₹Cr):** 19.6 → 22.1 → 20.5 → 20.0
Stable, not lumpy. No single-quarter spike distorting the picture.
---
## Management Commentary (Q4 FY26 Concall — May 2026)
Management tone score: **9/10** — one of the most credible concalls reviewed.
Key statements that build conviction:
- **Guided 20–22% EBITDA margins for FY27** — actively talked analysts DOWN from Q4's 23.9% to avoid overpromising. This is unusual and highly credible.
- **20–25% top-line growth guidance for EEI segment** — with near-full capacity today, this is backed by the Nashik capacity doubling commissioning June/July 2026.
- **US business target: ₹100 Cr in 3–4 years** — from near-zero today. One UL certification unlock = significant rerating.
- **Alucast demerger hinted** — "a possibility." If executed, this unlocks hidden value currently being discounted by the market due to the division's historical losses.
- **Dividend declared** — ₹2/share, signalling confidence in cash flows.
- **On solar:** "The more you sell, the more losses we were making — that is gone now." Breakeven crossed. Volume scale from here is margin-accretive.
One concern management flagged honestly: Lumel Alucast top-line will remain flat in FY27 as it rebuilds its contract book after shedding loss-making clients. This is a known, temporary drag — not a structural problem.
---
## Why Now — The Setup
- **PE compression paradox:** PE has gone from 36x (3 years ago) to 24x today — even as PAT has tripled. The stock is cheaper on earnings than it was when the business was weaker. This gap closes violently when institutions notice.
- **Capacity coming online:** Nashik doubling commissions June/July 2026. Revenue step-up is weeks away, not years.
- **CRS vs Nifty500 (50D): +44** — stock is significantly outperforming the broader market on a relative strength basis. Momentum is with the stock.
- **EMA alignment:** CMP ₹512 > EMA50 ₹482 > EMA200 ₹418. Bullish stack. No resistance overhead.
- **52-week high proximity:** Only 6 days since the last 52-week high. Stock is not tired — it is breaking out.
- **MCap ₹1,979 Cr** — small enough that one institutional discovery = 30–50% move.
---
## Buy Zone / Targets / Stop Loss
**Preferred entry zone: ₹490–520**
Current CMP ₹512 is inside the buy zone. Any dip toward EMA50 (₹482) is a gift entry.
**Do not chase above ₹545** — wait for a retest if missed.
| Target | Price | Basis | Timeline |
|---|---|---|---|
| Target 1 | ₹700 | PE re-rating to 32x on FY27E EPS of ~₹22 | 6–9 months |
| Target 2 | ₹850 | PE 36x on FY27E EPS — back to historical multiple | 12 months |
| Target 3 | ₹950 | Alucast demerger or US UL certification catalyst | 12–18 months |
**Stop Loss: ₹420** (just below EMA200 of ₹418)
A close below ₹420 invalidates the operating leverage thesis — exit cleanly.
**Risk/Reward:**
- Risk from CMP: ~18% downside to stop
- Reward to T2: ~66% upside
- Risk/Reward ratio: **~3.7:1**
---
## Key Risks to Monitor
1. **Solar inverter scaling slower than guided** — margin dilutive until breakeven volumes hit
2. **Alucast contract rebuild stalls** — top-line flat FY27 is known; any further deterioration is a red flag
3. **US UL certification delays** — the US ₹100 Cr target depends on approvals that involve "high costs, redesigns, and long lab queues" per management
4. **Global macro slowdown** — European demand subdued, any further weakness hurts Lumel revenue
---
## Summary
Rishabh Instruments is a rare combination: **globally competitive product, world-scale manufacturing in one niche (CTs), near-debt-free balance sheet, promoter holding 70%, OPM expanding 960bps in 12 months, PAT up 291% TTM, and a PE that has actually compressed.**
The market has not yet connected the dots between the earnings reality and the valuation. That gap is the opportunity.
The Nashik capacity doubling in June/July 2026 is the near-term trigger. The Alucast demerger and US expansion are the medium-term optionality.
**Buy ₹490–520 | Stop ₹420 | Target ₹850–950 | Timeframe 12–18 months**
*This is a research idea, not investment advice. Do your own due diligence.*
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.